Search company, investor...

Diabetogen Biosciences

Stage

Other Investors | Alive

About Diabetogen Biosciences

Diabetogen is a biotechnology company that discovers and develops new drugs for autoimmune diseases. Diabetogen's initial programs focus on the development of novel therapeutics for the treatment, prevention and cure of Type 1 (Insulin-Dependent) Diabetes. The company is committed to developing products that will replace, obviate or significantly reduce the need for insulin. In North America, 5% of adults, more than two-thirds of them are women, suffer from autoimmune diseases (including Type I diabetes, multiple sclerosis, rheumatoid arthritis, thyroiditis and systemic lupus erythematosus). Diabetogen's product strategy is to develop therapeutics designed to intervene in the progression of Type I Diabetes at each stage (antiCD28 fhmAb). Target market There are currently 1.65 million people in North America with Type 1 Diabetes. The direct cost of insulin therapy, supplemental medicines and monitoring, and diabetes related complications sum up to US $10,000 per patient per annum. In other words, it represents a US $16.5 billion per annum market in North America only. According to the World Health Organization (WHO), the total number of diabetics worldwide will more than double by the year 2025 to approximately 300 million people.

Headquarters Location

Ontario,

Canada

Loading...

Loading...

Diabetogen Biosciences Frequently Asked Questions (FAQ)

  • What is Diabetogen Biosciences's latest funding round?

    Diabetogen Biosciences's latest funding round is Other Investors.

  • Who are the investors of Diabetogen Biosciences?

    Investors of Diabetogen Biosciences include BDC Venture Capital.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.